Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for MDX2301 (Tetravalent Bispecific Antibody) in COVID-19 Infection. The expected timing is based on the latest available company guidance and may change.
07/27/26:- MDX2301 Phase 1 enrollment should complete Q3 2026; early data expected late 2026.
Verification
Confirm timing and program details against the company announcement or filing.